Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.66 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.64 |
| ▸ | TK2 | O00142 | 2/20 | 0.61 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.56 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.56 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14853822 | 1.00 | PYGM (0.66) | PYGMP2RY6TK2SLC28A1SLC28A2 | |
| SCHEMBL41141 | 1.00 | PYGM (0.66) | PYGMP2RY6TK2SLC28A1SLC28A2 | |
| SCHEMBL41142 | 1.00 | PYGM (0.66) | PYGMP2RY6TK2SLC28A1SLC28A2 | |
| Phosphoric Acid SCHEMBL9277556 | 0.95 | P2RY6 (0.68) | PYGMP2RY6TK2SLC28A1SLC28A2 | |
| SCHEMBL23782664 | 0.94 | PYGM (0.60) | PYGMP2RY6TK2 | |
| Pyrophosphoric Acid SCHEMBL9277601 | 0.92 | P2RY6 (0.74) | PYGMP2RY6TK2DNPH1P2RY2 | |
| SCHEMBL22807030 | 0.90 | PYGM (0.63) | PYGMP2RY6TK2SLC28A1SLC28A2 | |
| Netivudine SCHEMBL22028728 | 0.89 | P2RY6 (0.57) | PYGMP2RY6TK2SLC28A1SLC28A2 | |
| SCHEMBL21275602 | 0.89 | P2RY6 (0.56) | PYGMP2RY6TK2SLC28A1SLC28A2 | |
| SCHEMBL31155735 | 0.89 | P2RY6 (0.53) | PYGMP2RY6TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-22 | — | — | US | disclosed |
| EP-2931319-B1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| EP-2646449-B1 | URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | UNIV BAR ILAN (IL) | 2015-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | PYGM 1594/4885P2RY6 339/4885TK2 151/4885 |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | PYGM 1594/4885P2RY6 339/4885TK2 151/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PYGM 2038/4885P2RY6 2112/4885TK2 305/4885 |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PYGM 2038/4885P2RY6 2112/4885TK2 305/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PYGM 2038/4885P2RY6 2112/4885TK2 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.